About ImmunoSCAPE
ImmunoSCAPE is a company based in Singapore (Singapore) founded in 2016. ImmunoSCAPE has raised $39 million across 4 funding rounds from investors including Amgen, Anzu Partners and EDBI. ImmunoSCAPE offers products and services including TCR-based Therapeutics, Deep Immunomics Platform, and Machine Learning Platform. ImmunoSCAPE operates in a competitive market with competitors including Reaction Biology, PhenoVista, Discovery Biomed, BCI Pharma and ICE Bioscience, among others.
- Headquarter Singapore, Singapore
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunoscape Pte Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$39 M (USD)
in 4 rounds
-
Latest Funding Round
$14 M (USD), Series B
Sep 20, 2022
-
Investors
Amgen
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmunoSCAPE
ImmunoSCAPE offers a comprehensive portfolio of products and services, including TCR-based Therapeutics, Deep Immunomics Platform, and Machine Learning Platform.
Develops novel T cell receptor therapies targeting solid tumors.
Platform for discovering TCRs using immunomics and machine learning.
Applies AI to identify and optimize TCR-based therapeutic candidates.
People of ImmunoSCAPE
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ImmunoSCAPE
ImmunoSCAPE has successfully raised a total of $39M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImmunoSCAPE
ImmunoSCAPE has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Anzu Partners and EDBI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in industrial and life sciences technology companies.
|
Locked | Locked | Locked | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked | |
|
Seed and Early stage VC firm investing in Japan
|
Locked | Locked | Locked |
Investor details for ImmunoSCAPE
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImmunoSCAPE
Investment portfolio details for ImmunoSCAPE
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImmunoSCAPE
Detailed financials for ImmunoSCAPE
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunoscape Comparisons
Peer comparison for ImmunoSCAPE
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImmunoSCAPE
ImmunoSCAPE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, PhenoVista, Discovery Biomed, BCI Pharma and ICE Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| Locked | Locked | Locked |
A CRO that provides phenotypic assay development and screening services.
|
|
| Locked | Locked | Locked |
Custom human cell engineering and drug discovery services are provided.
|
|
| Locked | Locked | Locked |
Contract research services in cancer and neuroinflammation are offered.
|
|
| Locked | Locked | Locked |
Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and in vitro HTS screening
|
Detailed competitors of ImmunoSCAPE
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunoscape
Complete news archive for ImmunoSCAPE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunoSCAPE
ImmunoSCAPE was founded in 2016 and raised its 1st funding round 4 years after it was founded.
ImmunoSCAPE is headquartered in Singapore, Singapore.
ImmunoSCAPE is a funded company, having raised a total of $39M across 4 funding rounds to date.
ImmunoSCAPE was founded in 2016 in Singapore as a spin-off from Dr. Evan Newells lab at ASTARs Singapore Immunology Network. Services focus on biomarker and target identification in immunology, using mass cytometry for immune cell and T-cell analysis in oncology and infectious diseases. Operations involve antigen discovery, cell profiling, and data tools to support RD, including surrogate marker identification, disease progression assessment, and efficacy evaluation in preclinical and clinical phases.
ImmunoSCAPE's top competitors include Quantumcyte, Reaction Biology and PhenoVista.
ImmunoSCAPE offers TCR-based Therapeutics, Deep Immunomics Platform, and Machine Learning Platform.
ImmunoSCAPE has 4 investors. Key investors include Amgen, Anzu Partners, EDBI, and UT-EC Japan.